Informatie:
Fout:
ID
18920
Beschrijving
ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body; ODM derived from: https://clinicaltrials.gov/show/NCT00061126
Link
https://clinicaltrials.gov/show/NCT00061126
Trefwoorden
Versies (1)
- 24-11-16 24-11-16 -
Geüploaded op
24 november 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Prostate Cancer NCT00061126
Eligibility Prostate Cancer NCT00061126
- StudyEvent: Eligibility
Similar models
Eligibility Prostate Cancer NCT00061126
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Gender | Age
Item
male 18 years of age or older
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
Tumor tissue Available diagnostic use
Item
has tumor tissue available for diagnostics
boolean
C0475358 (UMLS CUI [1,1])
C0470187 (UMLS CUI [1,2])
C0011933 (UMLS CUI [1,3])
C0470187 (UMLS CUI [1,2])
C0011933 (UMLS CUI [1,3])
Luteinizing Hormone-releasing Hormone Agonist Primary failed | Leuprolide | Goserelin | Orchiectomy failed | Disease Progression | Luteinizing Hormone-releasing Hormone Agonist Continue | Orchiectomy
Item
failed front line luteinizing hormone-releasing hormone analogue (lhrh) such as leuprolide or goserelin, or failed orchiectomy, as evidenced by disease progression. patients must continue on a lhrh analogue (unless the patient had an orchiectomy) throughout the course of the study
boolean
C1518041 (UMLS CUI [1,1])
C0205225 (UMLS CUI [1,2])
C0231175 (UMLS CUI [1,3])
C0085272 (UMLS CUI [2])
C0120107 (UMLS CUI [3])
C0029189 (UMLS CUI [4,1])
C0231175 (UMLS CUI [4,2])
C0242656 (UMLS CUI [5])
C1518041 (UMLS CUI [6,1])
C0549178 (UMLS CUI [6,2])
C0029189 (UMLS CUI [7])
C0205225 (UMLS CUI [1,2])
C0231175 (UMLS CUI [1,3])
C0085272 (UMLS CUI [2])
C0120107 (UMLS CUI [3])
C0029189 (UMLS CUI [4,1])
C0231175 (UMLS CUI [4,2])
C0242656 (UMLS CUI [5])
C1518041 (UMLS CUI [6,1])
C0549178 (UMLS CUI [6,2])
C0029189 (UMLS CUI [7])
ECOG performance status
Item
ecog score of 0 or 1
boolean
C1520224 (UMLS CUI [1])
Prior Chemotherapy Prostate carcinoma | Hormone Therapy | Agent Epidermal Growth Factor Receptor Targeting
Item
any prior chemotherapy for prostate cancer besides hormonal therapy (including no prior egfr targeting agent)
boolean
C1514457 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C0279025 (UMLS CUI [2])
C1254351 (UMLS CUI [3,1])
C0034802 (UMLS CUI [3,2])
C1521840 (UMLS CUI [3,3])
C0600139 (UMLS CUI [1,2])
C0279025 (UMLS CUI [2])
C1254351 (UMLS CUI [3,1])
C0034802 (UMLS CUI [3,2])
C1521840 (UMLS CUI [3,3])
Malignant Neoplasms Requirement Therapeutic procedure | Prostate carcinoma | Basal cell carcinoma
Item
prior history of cancer other than prostate carcinoma within the past 5 years that has required treatment or been active (prior basal cell carcinoma is allowed)
boolean
C0006826 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C0600139 (UMLS CUI [2])
C0007117 (UMLS CUI [3])
C1514873 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C0600139 (UMLS CUI [2])
C0007117 (UMLS CUI [3])
HIV Seropositivity
Item
known to be hiv positive
boolean
C0019699 (UMLS CUI [1])
Myocardial Infarction
Item
myocardial infarction within one year prior to entering the study
boolean
C0027051 (UMLS CUI [1])